Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Inflammation Research
Published in: Inflammation Research 1/2013

01-01-2013 | Original Research Paper

Anti-inflammatory and anti-arthritic activities of 3,4-dihydro-2,2-dimethyl-2H-naphthol[1,2-b]pyran-5,6-dione (β-lapachone)

Authors: Marília Maria Sitônio, Carlson H. R. de Carvalho Júnior, Ingrid de A. Campos, José Bruno Nunes Ferreira Silva, Maria do Carmo Alves de Lima, Alexandre J. S. Góes, Maria Bernadete Sousa Maia, Pedro J. Rolim Neto, Teresinha G. Silva

Published in: Inflammation Research | Issue 1/2013

Login to get access

Abstract

Objective and design

The purpose of this study was to evaluate the anti-inflammatory and anti-arthritic activities of 3,4-dihydro-2,2-dimethyl-2H-naphthol[1,2-b]pyran-5,6-dione (β-lapachone; β-lap) and to elucidate its probable mode of action.

Methods

Carrageenan-induced paw edema, cell migration evaluation and production of pro-inflammatory cytokines tumor necrosis factor (TNF)-α, interleukin (IL)-6 and nitric oxide were used for this study. Freund’s complete adjuvant (FCA)-induced arthritis was used as a model of chronic inflammation. β-Lap was tested in doses of 40 and 60 mg/kg, orally.

Results

In the paw edema test, the dose of 60 mg/kg gave a higher percentage inhibition of edema (49.3 %) than control. β-Lap inhibited neutrophil migration and reduced concentrations of TNF-α, IL-6 and NO in peritoneal exudates of animals with peritonitis. In the arthritis test, β-lap inhibited edema and NO production in the serum of treated animals.

Conclusion

Significant anti-inflammatory and anti-arthritic activities were observed in animals treated with β-lap. The effects of β-lap can be attributed in part to immunomodulation with reduction of pro-inflammatory cytokines and NO.
Literature
1.
Moon DO, Kang CH, Kim MO, Jeon YJ, Lee JD, Choi YH, Kim GY. β-Lapachone (LAPA) decreases cell viability and telomerase activity in leukemia cells: suppression of telomerase activity by LAPA. J Med Food. 2010;13:481–8.PubMedCrossRef
2.
Ferreira SB, Salomão K, Silva FC, Pinto AV, Kaiser CR, Pinto AC, Ferreira VF, Castro SI. Synthesis and anti-Trypanosoma cruzi activity of β-lapachone analogues. Eur J Med Chem. 2011;46:3071–7.PubMedCrossRef
3.
De Almeida ER, da Silva Filho AA, dos Santos ER, Lopes CA. Anti-inflammatory action of lapachol. J Ethnopharmacol. 1990;29:239–41.PubMedCrossRef
4.
Tzeng HP, Ho FM, Chao KF, Kuo ML, Lin-Shiau SY, Liu SH. Beta-Lapachone reduces endotoxin-induced macrophage activation and lung edema and mortality. Am J Respir Crit Care Med. 2003;168:85–91.PubMedCrossRef
5.
Guiraud P, Steiman R, Campos-Takaki GM, Seigle-Murandi F, Simeon de BM. Comparison of antibacterial and antifungal activities of lapachol and beta-lapachone. Planta Med. 1994;60:373–4.PubMedCrossRef
6.
Pereira EM. Machado Tde B, Leal IC, Jesus DM, Damaso CR, Pinto AV, Giambiagi-de Marval M, Kuster RM, Santos KR. Tabebuia avellanedae naphthoquinones: activity against methicillin-resistant staphylococcal strains, cytotoxic activity and in vivo dermal irritability analysis. Ann Clin Microbiol Antimicrob. 2006;22(5):5.CrossRef
7.
Oliveira RA, Azevedo-Ximenes E, Luzzati R, Garcia RC. The hydroxy-naphthoquinone lapachol arrests mycobacterial growth and immunomodulates host macrophages. Int Immunopharmacol. 2010;10:1463–73.PubMedCrossRef
8.
Li CJ, Zhang LJ, Dezube BJ, Crumpacker CS, Pardee AB. Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication. Proc Natl Acad Sci USA. 1993;90:1839–42.PubMedCrossRef
9.
Kung HN, Yang MJ, Chang CF, Chau YP, Lu KS. In vitro and in vivo wound healing-promoting activities of β-lapachone. Am J Physiol Cell Physiol. 2008;295:931–43.CrossRef
10.
Schuerch AR, Wehrli W. Beta-Lapachone, an inhibitor of oncornavirus reverse transcriptase and eukaryotic DNA polymerase-alpha. Inhibitory effect, thiol dependence and specificity. Eur J Biochem. 1978;84:197–205.PubMedCrossRef
11.
Boorstein RJ, Pardee AB. Coordinate inhibition of DNA synthesis and thymidylate synthase activity following DNA damage and repair. Biochem Biophys Res Commun. 1983;117:30–6.PubMedCrossRef
12.
Li YZ, Li CJ, Pinto AV, Pardee AB. Release of mitochondrial cytochrome c in both apoptosis and necrosis induced by beta-lapachone in human carcinoma cells. Mol Med. 1999;5:232–9.PubMed
13.
Chau YP, Shiah SG, Don MJ, Kuo ML. Involvement of hydrogen peroxide in topoisomerase inhibitor b-lapachone-induced apoptosis and differentiation in human leukemia cells. Free Radic Biol Med. 1998;24:660–70.PubMedCrossRef
14.
Li CJ, Averboukh L, Pardee AB. Beta-lapachone, a novel DNA topoisomerase I inhibitor with a mode of action different from camptothecin. J Biol Chem. 1993;268:22463–8.PubMed
15.
Krishnan P, Bastow KF. Novel mechanism of cellular DNA topoisomerase II inhibition by the pyranonaphthoquinone derivatives alpha-lapachone and beta-lapachone. Cancer Chemother Pharmacol. 2001;47:187–98.PubMedCrossRef
16.
Jackson JK, Higo T, Hunter WL, Burt HM. Topoisomerase inhibitors as anti-arthritic agents. Inflamm Res. 2008;57:126–34.PubMedCrossRef
17.
Tudan C, Jackson J, Higo TT, Burt HM. The effect of inhibiting topoisomerase I and II on the anti-apoptotic response associated with pro-inflammatory crystals of calcium pyrophosphate dihydrate in human neutrophils. Inflamm Res. 2003;52:8–17.PubMedCrossRef
18.
De Miranda FG, Vilar JC, Alves IA, Cavalcanti SC, Antoniolli AR. Antinociceptive and antiedematogenic properties and acute toxicity of Tabebuia avellanedae Lor. ex Griseb. inner bark aqueous extract. BMC Pharmacol. 2001;1:6.PubMedCrossRef
19.
Wanick MC, Bandeira JÁ, Fernandes RV. Ação antiinflamatória e cicatrizante do extrato hidroalcoólico do Líber do Pau d’arco Roxo (Tabebuia avellanedae), em pacientes portadores de Cervicites e Cérvico-vaginites. Rev Inst Antibióticos. 1970;10:41–6.
20.
Liu SH, Tzeng HP, Kuo ML, Lin-Shiau SY. Inhibition of inducible nitric oxide synthase by beta-lapachone in rat alveolar macrophages and aorta. Br J Pharmacol. 1999;126:746–50.PubMedCrossRef
21.
Manna SK, Gad YP, Mukhopadhyay A, Aggarwal BB. Suppression of tumor necrosis factor activated nuclear transcription factor-kB, activator protein-1, c-Jun N-terminal kinase, and apoptosis by β-lapachone. Biochem Pharmacol. 1999;57:763–74.PubMedCrossRef
22.
Smith HS, Smith AR, Seidner P. Painful rheumatoid arthritis. Pain Physician. 2011;14:E427–58.PubMed
23.
Bansback NJ, Regier DA, Ara R, Brennan A, Shojania K, Esdaile JM, Anis AH, Marra CA. An overview of economic evaluations for drugs used in rheumatoid arthritis: focus on tumour necrosis factor-alpha antagonists. Drugs. 2005;65:473–96.PubMedCrossRef
24.
Lin HS, Hu CY, Chan HY, Liew YY, Huang HP, Lepescheux L, Bastianelli E, Baron R, Rawadi G, Clément-Lacroix P. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol. 2007;150:862–72.PubMedCrossRef
25.
Klinkhoff A. Biological agents for rheumatoid arthritis: targeting both physical function and structural damage. Drugs. 2004;64:1267–83.PubMedCrossRef
26.
Cavalcante FA, Silva JLV, Carvalho VMN, Camara CA, Silva TM, Pinto AC, et al. Spasmolytic activity of lapachol and its derivatives, alpha and beta-lapachone, on the guinea-pig ileum involves blockade of voltage-gated calcium channels. Rev Bras Farmacog. 2008;18:183–9.CrossRef
27.
Winter CA, Risley EA, Nuss GW. Carrageenin-induced edema in hind paw of the rat as an assay for antiiflammatory drugs. Proc Soc Exp Biol Med. 1962;111:544–7.PubMed
28.
Ough M, Lewis A, Bey EA, Gao J, Ritchie JM, Bornmann W, Boothman DA, Oberley LW, Cullen JJ. Efficacy of b-lapachone in pancreatic cancer treatment. Cancer Biol Ther. 2005;4:95–102.PubMedCrossRef
29.
Guerra AS, Malta DJ, Laranjeira LP, Maia MB, Colaço NC, De Lima MC, Galdino SL, Pitta IR, Gonçalves-Silva T. Anti-inflammatory and antinociceptive activities of indole-imidazolidine derivatives. Int Immunopharmacol. 2011;11:1816–22.PubMedCrossRef
30.
Newbould BB. Chemotherapy of arthritis induced in rats by mycobacterial adjuvant. Br J Pharmacol. 1963;21:127–36.
31.
McCartney-francis N, Allen JB, Mizel DE, Albina JE, Xie QW, Nathan CF, Wahl SM. Suppression of arthritis by an inhibitor of nitric oxide synthase. J Exp Med. 1993;178(2):749–54.PubMedCrossRef
32.
Salvemini D, Wang ZQ, Wyatt PS, Bourdon DM, Marino MH, Manning PT, Currie MG. Nitric oxide: a key mediator in the early and late phase of carrageenan-induced rat paw inflammation. Br J Pharmacol. 1996;118:829–38.PubMedCrossRef
33.
Pèrez-gurrero C, Herrera MD, Ortiz R. De sotomayor MA, Fernández MA. A pharmacological study of Cecropia obtusifolia Betrol aqueous extract. J Ethnopharmacol. 2001;76:279–84.CrossRef
34.
Faria L, Antunes E, Bom C, Araújo AL. Pharmacological characterization of the rat paw edema induced by Bothrops lanceolatus (Fer de lance) venom. Toxicon. 2001;39:825–30.PubMedCrossRef
35.
Prasad N, Gupta A. Fungal peritonitis in peritoneal dialysis patients. Perit Dial Int. 2005;25(3):207–22.PubMed
36.
Foster SJ, McCormick ME, Howarth A, Aked D. Leukocyte recruitment in the subcutaneous sponge implant model of acute inflammation in the rat is not mediated by leukotriene B1. Biochem Pharmacol. 1986;35:1709–17.PubMedCrossRef
37.
Kim JY, Hwang YP, Kim DH, Han EH, Chung YC, Roh SH, et al. Inhibitory effect of the saponins derived from roots of Platycodon grandiflorum on carrageenan-induced inflammation. Biosci Biotechnol Biochem. 2006;70:858–64.PubMedCrossRef
38.
Loram LC, Fuller A, Fick LG, Cartmell T, Poole S, Mitchell D. Cytokine profiles during carrageenan-induced inflammatory hyperalgesia in rat muscle and hind paw. J Pain. 2007;8:127–36.PubMedCrossRef
39.
Vigil SVG, Liz R, Medeiros YS, Fröde TS. Efficacy of tacrolimus in inhibiting inflammation caused by carrageenan in a murine model of air pouch. Transpl Immunol. 2008;19:25–9.PubMedCrossRef
40.
41.
Junior VLLP, Rebelo MC, Gomes RN, Assis EF, Neto HCCF, Bóia MN. Il-6 and Il-8 in cerebrospinal fluid from patients with aseptic meningitis and bacterial meningitis: their potential role as a marker for differential diagnosis. Braz J Infect Dis. 2011;15(2):156–8.
42.
Kinne RW, Stuhlmuller B, Burmester GR. Cells of the synovium in rheumatoid arthritis macrophages. Arthritis Res Ther. 2007;9:224–40.PubMedCrossRef
43.
Taylor PC, Feldmann M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol. 2009;5:578–82.PubMedCrossRef
44.
Grabowski PS, Wright PK, Vanthof RJ, Helfrich MH, Ohshima H, Ralston SH. Immunolocalization of inducible nitric oxide synthase in synovium and cartilage in rheumatoid arthritis and osteoarthritis. Br J Rheumatol. 1997;36:651–5.PubMedCrossRef
45.
Fermor B, Christensen SE, Youn I, Cernanec JM, Davies CM, Weinberg JB. Oxygen, nitric oxide and articular cartilage. Eur Cell Mater. 2007;13:56–65.PubMed
Metadata
Title
Anti-inflammatory and anti-arthritic activities of 3,4-dihydro-2,2-dimethyl-2H-naphthol[1,2-b]pyran-5,6-dione (β-lapachone)
Authors
Marília Maria Sitônio
Carlson H. R. de Carvalho Júnior
Ingrid de A. Campos
José Bruno Nunes Ferreira Silva
Maria do Carmo Alves de Lima
Alexandre J. S. Góes
Maria Bernadete Sousa Maia
Pedro J. Rolim Neto
Teresinha G. Silva
Publication date
01-01-2013
Publisher
SP Birkhäuser Verlag Basel
Published in
Inflammation Research / Issue 1/2013
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-012-0557-0

Other articles of this Issue 1/2013

Inflammation Research 1/2013 Go to the issue

Review

Endothelial progenitor cells: the promise of cell-based therapies for acute lung injury

Original Research Paper

Lipopolysaccharide/adenosine triphosphate-mediated signal transduction in the regulation of NLRP3 protein expression and caspase-1-mediated interleukin-1β secretion

Original Research Paper

FcγRIIa requires lipid rafts, but not co-localization into rafts, for effector function

Original Research Paper

Association of interleukin-1 gene polymorphisms with multiple sclerosis: a meta-analysis

Original Research Paper

Anti-arthritic activity of the Indian leafy vegetable Cardiospermum halicacabum in Wistar rats and UPLC–QTOF–MS/MS identification of the putative active phenolic components

Editorial

Journal status and new developments
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits